Issue 7, 2014                Board of Directors Office               April 17, 2014

                       
     
      On April 13, 2014, Daphne Danshen Heart Capsules were discussed at a meeting held in the Anhui Building, Beijing. The meeting was attended by pharmaceutical & clinical research experts from the State TCM Protection Review Commission, including Zhang Shichen, vice chairman at the China Association of Traditional Chinese Medicine, former chief of the Registration Department at China FDA and leader of the State TCM Protection Review Commission Review Management Team; Ji Shaoliang and Gao Xuemin, professor at the Beijing University of Chinese Medicine and leader of the State TCM Protection Review Commission review medical team; Zhou Furong and Lin Qian, former chief of the Beijing Institute for Drug Control TCM Room and leader of the State TCM Protection Review Commission Review Pharmaceutical Team; chief of the Department of Cardiology at Beijing University of Chinese Medicine Oriental Hospital and clinical review expert of the State TCM Protection Review Commission; Lu Weixing, chief of the Department of Cardiology at the Beijing University of Chinese Medicine No. 3 Affiliated Hospital and clinical review expert of the State TCM Protection Review Commission; and Rao Gaoxiong, president and professor at Yunnan University of TCM.  
      At the meeting, the experts provided many valuable opinions on our preparation in pharmacy for the review commission and clinical research scheme, and affirmed the clinical effect of Daphne Danshen Heart Capsules. In the end, consensus was reached on the clinical experimental program. 
      The meeting is a part of preparation for clinical research of the Danshen Heart Capsules State TCM Protection Review Commission, in order to make decision on inclusion of the drug in the list of protected TCM drugs. With support of the experts, we believe that the medical and clinical research can be completed smoothly.